ERCC2 and urinary bladder carcinoma: To explore if ERCC2 helicase-domain mutations may predict cisplatin response in bladder cancer, we investigated the relationship between ERCC2 helicase-domain mutation status (Figure 4A) and patient outcomes in the assembled bladder cancer cohorts.